adalimumab

Approved Monoclonal Antibody Therapies for Hidradenitis Suppurativa: Efficacy, Safety, and Economic Assessments

This review synthesizes current evidence on adalimumab, secukinumab, and bimekizumab for moderate-to-severe hidradenitis suppurativa, emphasizing clinical efficacy, safety, mechanistic insights, and cost-effectiveness across diverse health